The Chosun Ilbo on MSN

GC Biopharma expands Alyglo indications to pediatric patients

GC Biopharma is accelerating its global market strategy, centered on its flagship product “Alyglo.” The company aims to build a mid- to long-term growth foundation by expanding the scope of ...
Fierce Pharma

Biogen pays $20M upfront to tap into Alteogen's subQ delivery tech

After attracting GSK with its subcutaneous delivery tech at the top of the year, South Korea’s Alteogen has snared another ...
The Manila Times

Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics

Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4 ...
The American Journal of Managed Care

Overcoming Barriers and Future Integration of Subcutaneous Therapies in Lung Cancer

In the final episode, Overcoming Barriers and Future Integration of Subcutaneous Therapies in Lung Cancer, the panelists ...
StockStory.org on MSN

Unpacking Q4 earnings: Halozyme Therapeutics (NASDAQ:HALO) in the context of other therapeutics stocks

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...